Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

NCT ID: NCT00168259

Last Updated: 2012-01-20

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 20 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2004-12-31
• Study Completion Date: 2009-12-31

Brief Summary

The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

Conditions

HIV Infection; CMV Infection

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. HIV positive with history of documented HCV infection

2. Over 18 years old

3. HIV positive

4. Antiretroviral naive, starting on antiretroviral therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cellestis

INDUSTRY

Sponsor Role: collaborator

The Alfred

OTHER

Sponsor Role: lead

Responsible Party

Jennifer Hoy

Professor Jennifer Hoy

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sharon Lewin, Professor

Role: PRINCIPAL_INVESTIGATOR

The Alfred

Locations

Alfred Hospital

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

185/04

Identifier Type: -

Identifier Source: org_study_id